突破性疗法指定-话题@MedSci

#突破性疗法指定#

4篇内容 | 557人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1986466, encodeId=9cd7198646645, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性疗法指定#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=34, createdTime=2020-04-29, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986465, encodeId=65a01986465d9, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性疗法指定#</a>, objectTitle=Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定, objectType=article, longId=180107, objectId=1e3218010eb7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e3218010eb7, replyNumber=0, likeNumber=47, createdTime=2020-04-11, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e3218010eb7, moduleTitle=Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e3218010eb7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986464, encodeId=bfdd1986464e9, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性疗法指定#</a>, objectTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, objectType=article, longId=178985, objectId=41461e898555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41461e898555, replyNumber=0, likeNumber=33, createdTime=2020-05-02, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41461e898555, moduleTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41461e898555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986463, encodeId=b03a1986463c6, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性疗法指定#</a>, objectTitle=治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定, objectType=article, longId=117910, objectId=9e7d11e910f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e7d11e910f4, replyNumber=0, likeNumber=38, createdTime=2017-12-21, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e7d11e910f4, moduleTitle=治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e7d11e910f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

突破性疗法指定

2020-05-29

Boyinsh (审核中...)

前往app查看评论内容

#突破性疗法指定#

Janssen宣布FDA授予其PARP抑制剂Niraparib治疗转移性去势抵抗性前列腺癌的突破性疗法指定

2020-04-29

Boyinsh (审核中...)

前往app查看评论内容

#突破性疗法指定#

Achillion的D因子抑制剂Danicopan治疗阵发性夜间血红蛋白尿，获得FDA突破性疗法指定

2020-04-11

Boyinsh (审核中...)

前往app查看评论内容

#突破性疗法指定#

Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性疗法指定

2020-05-02

Boyinsh (审核中...)

前往app查看评论内容

#突破性疗法指定#

治疗大 B 细胞淋巴瘤又一单抗获 FDA 突破性疗法指定

2017-12-21

科室
- - 订阅+
  - 更多科室
工具
服务